Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling by Stevens-Kroef, M.J.P.L. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/138213
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
CytoScan HD HumanOmniExpress
A
Case 9
Chr. 17
D
Case 11
Chr. 11
C
Case 18
Chr. 15q15.1
B
Case 16
Chr. 17p13.1
E
Case 21
Chr. 17
Lo
g2
 ra
tio
S-
lo
g2
 
AP
TP53
MGA
Lo
g2
 ra
tio
Lo
g2
 ra
tio
Lo
g2
 ra
tio
Lo
g2
 ra
tio
S -
lo
g2
 
S-
lo
g2
 
S -
lo
g2
 
S-
lo
g2
 
Lo
g2
 ra
tio
MGA
Lo
g2
 ra
tio
Lo
g2
 ra
tio
Lo
g2
 ra
tio TP53
Identification of prognostic relevant chromosomal
abnormalities in chronic lymphocytic leukemia
using microarray-based genomic profiling
Stevens-Kroef et al.
Stevens-Kroef et al. Molecular Cytogenetics 2014, 7:3
http://www.molecularcytogenetics.org/content/7/1/3
RESEARCH Open Access
Identification of prognostic relevant chromosomal
abnormalities in chronic lymphocytic leukemia
using microarray-based genomic profiling
Marian JPL Stevens-Kroef1*, Eva van den Berg2, Daniel Olde Weghuis1, Ad Geurts van Kessel1, Rolph Pfundt1,
Matty Linssen-Wiersma1, Marloes Benjamins2, Trijnie Dijkhuizen2, Patricia JTA Groenen3 and Annet Simons1
Abstract
Background: Characteristic genomic abnormalities in patients with B cell chronic lymphocytic leukemia (CLL) have
been shown to provide important prognostic information. Fluorescence in situ hybridization (FISH) and multiplex
ligation-dependent probe amplification (MLPA), currently used in clinical diagnostics of CLL, are targeted tests
aimed at specific genomic loci. Microarray-based genomic profiling is a new high-resolution tool that enables
genome-wide analyses. The aim of this study was to compare two recently launched genomic microarray platforms,
i.e., the CytoScan HD Array (Affymetrix) and the HumanOmniExpress Array (Illumina), with FISH and MLPA to
ascertain whether these latter tests can be replaced by either one of the microarray platforms in a clinical diagnostic
setting.
Result: Microarray-based genomic profiling and FISH were performed in all 28 CLL patients. For an unbiased
comparison of the performance of both microarray platforms 9 patients were evaluated on both platforms,
resulting in the identification of exactly identical genomic aberrations. To evaluate the detection limit of the
microarray platforms we included 7 patients in which the genomic abnormalities were present in a relatively low
percentage of the cells (range 5-28%) as previously determined by FISH. We found that both microarray platforms
allowed the detection of copy number abnormalities present in as few as 16% of the cells. In addition, we found
that microarray-based genomic profiling allowed the identification of genomic abnormalities that could not be
detected by FISH and/or MLPA, including a focal TP53 loss and copy neutral losses of heterozygosity of
chromosome 17p.
Conclusion: From our results we conclude that although the microarray platforms exhibit a somewhat lower limit
of detection compared to FISH, they still allow the detection of copy number abnormalities present in as few as
16% of the cells. By applying similar interpretation criteria, the results obtained from both platforms were
comparable. In addition, we conclude that both microarray platforms allow the identification of additional potential
prognostic relevant abnormalities such as focal TP53 deletions and copy neutral losses of heterozygosity of
chromosome 17p, which would have remained undetected by FISH or MLPA. The prognostic relevance of these
novel genomic alterations requires further evaluation in prospective clinical trials.
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Background
B-cell chronic lymphocytic leukemia (CLL) exhibits a
highly heterogeneous clinical course, with overall sur-
vival rates varying from several months to decades.
Whereas several prognostic markers, such as expression
of the CD38 and ZAP70 proteins are well-established
now, these markers do not allow the identification of all
patients with a high risk profile. Mutation status of the
IGHV genes and specific genomic abnormalities, such as
deletion of 11q22, trisomy of chromosome 12 and loss
of the 13q14 region, provide additional prognostic infor-
mation [1,2]. In addition, deletion of 17p and/or the
presence of a TP53 mutation, which are both associated
with a poor prognosis, identify CLL patients with the
highest risk profile [2]. Conventional cytogenetic ana-
lyses result in the identification of genetic abnormalities
in a relatively low percentage of patients, due to the low
in vitro proliferative potential of CLL cells. Even after
recent improvements of this technique, using CpG-
oligonucleotide DSP30 and interleukin-2 (IL-2) [3], it
still does not allow the detection of submicroscopic losses
such as those of the 11q, 13q and 17p regions. The most
common molecular-cytogenetic techniques currently used
to detect these abnormalities in CLL are fluorescence in
situ hybridization (FISH) [1] and multiplex ligation-
dependent probe amplification (MLPA) [4]. However,
since FISH analysis of multiple loci is relatively labori-
ous, and since both FISH and MLPA are targeted tests
providing limited views on the genomic landscapes of
CLL cells, we aimed to evaluate the diagnostic efficacy
of microarray-based whole genome profiling. Next to its
genome-wide character, microarray-based genomic pro-
filing also allows the detection of small cryptic copy
number alterations (CNAs) and copy neutral losses of
heterozyogosity (CNLOH) that remain undetected by
FISH and MLPA [5,6].
The specific aim of the present study was to compare
the CytoScan HD Array platform from Affymetrix and
the HumanOmniExpress 12v1 Array platform from Illu-
mina on one hand with FISH and MLPA on the other
hand by employing the currently used probe panels, tar-
geting the chromosome regions 11q22, 13q14 and 17p13
and chromosome 12 for the detection of clinically rele-
vant chromosomal abnormalities in CLL. To ascertain
which approach would be most suitable in a routine
cytogenetic diagnostic setting we also evaluated their
limit of detection for the identification of small CLL
(sub)clones and their resolution with respect to the de-
tection of small focal genomic abnormalities.
Results
Microarray-based identification of genomic abnormalities
Microarray-based genomic profiling (12 patients with
the CytoScan HD Array platform only; 7 patients with
HumanOmniExpress Array platform; 9 patients on both
platforms) was performed on peripheral blood or bone
marrow samples from 28 CLL patients (Tables 1 and 2).
In 24 of these patients genomic abnormalities (CNAs
and CNLOH) were identified by microarray-based pro-
filing: 5 cases (cases 2, 8, 14, 26 and 27) showed only
one aberration (all involving loss of the 13q14 region or
gain of chromosome 12), 5 cases (cases 5, 6, 16, 17 and
24) showed 2 aberrations (9 CNAs and 1 CNLOH), 5 cases
(cases 7, 10, 15, 20 and 23) showed 3 aberrations (13 CNAs
and 2 CNLOH), and 9 cases (cases 3, 4, 9, 11, 12, 18, 21,
25 and 28) showed more than 3 aberrations (46 CNAs and
3 CNLOH). The remaining 4 cases (1, 13, 19 and 22)
showed normal microarray-based genomic profiles.
High limit of detection and resolution of both microarray
platforms as compared to FISH and MLPA
Microarray-based genomic profiling with the CytoScan
HD Array and/or the HumanOmniExpress platform were
applied to all 28 patients. For an unbiased comparison of
the performance of both microarray platforms 9 patients
(cases 7, 9, 10, 11, 16, 17, 18, 19 and 20) were evaluated
on both microarray platforms in a fully blinded fashion,
using identical interpretation criteria (see Methods sec-
tion). By doing so, we found that both microarray plat-
forms revealed exactly identical genomic aberrations
(CNA and CNLOH). For representative examples see
Figure 1.
For assessment of the limit of detection of the micro-
array platforms, 7 cases (cases 7, 9, 10, 11, 17, 20 and
24) were selected, since in these cases the genomic ab-
normalities were present in relatively low percentages of
the cells (range 5-28%) as determined by FISH. All ab-
normalities present in more than 16% of the cells were
readily detected by both microarray platforms, including
3 cases with a trisomy (cases 17 and 24 both with a tri-
somy 12 in 21% of the cells, and case 10 with a trisomy
8 in 28% of the cells), 3 cases (cases 7, 9 and 10) with
loss of 17p in 16% to 21% of the cells (Figure 1A), and
case 11 with loss of 13q14 in 28% of the cells. Case 20
was included in this study since 5% of its peripheral
blood cells contained a bi-allelic loss of 13q14 as deter-
mined by FISH. Using the Cytoscan HD Array platform,
this latter 1.7 Mb loss on 13q14 was barely detectable,
whereas it was below detection level using the Huma-
nOmniExpress Array platform.
For assessment of the resolution of both microarray plat-
forms, case 16 was used since this case harbors focal loss
of the TP53 gene as determined by MLPA. This loss was
not detected by the FISH probe used, since approximately
half of the probe covered a non-deleted segment. Using
both microarray platforms we found that the ~350 kb loss
encompassing the TP53 gene could readily be detected
(Figure 1B).
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Table 1 Overview of genetic abnormalites as determined
by FISH, MLPA and microarray-based genomic profiling
Patient
ID
FISH (% of
abnormal cells)
MLPA Microarray-based genomic
profiling
Recurrent Additional
1 Not done Normal Normal
2 Not done Loss 13q14 Loss 13q14
3 Not done Loss 13q14* Loss 13q14* Loss 6p
Loss 17p13 Loss 17p13 CNLOH 13q
4 Not done Loss 11q22 Loss 11q22 Gain 2p
Loss 13q14 Loss 13q14 Loss 6p
Loss 7q
5 Not done Gain 12 Gain 12 Loss 1q
6 Not done 13q14 Loss 13q14* Loss 13q14*
Normal 11q22
Normal 17p13
7 Normal 11q22 Loss 1q
Not done 12 Gain 12 Gain 12
Loss 17p13
(21%)
Loss 17p13 Loss 17p13
8 Not done Loss 13q14 Loss 13q14
9 Normal 11q22 Loss 17p13 Loss 17p13 Gain 2p
Loss 17p13
(21%)
Loss 6q
Gain 17p11
Loss 20p
10 Gain 8 (28%) Loss 17p13 Loss 17p13 Gain 8
Loss 17p13
(16%)
Gain 17q
Normal 11q22
11 Loss 11q22
(58%)
Loss 11q22 Loss 11q22 Gain Xq
Normal CEP 12 Gain 12q Loss 3q
Loss 13q14
(28%)
Loss 13q14 Loss 13q14 Loss 11p
Normal 17p13 Gain 12q
12 Not done Loss 17p13 Loss 17p13 Gain 3q22
Loss 6q
Gain 19p
13 Not done Normal Normal
14 Not done Gain 12 Gain 12
15 Not done Gain 12 Gain 12 Gain 18
Gain 19
16 Loss 13q14
(75%)
Loss 13q14 Loss 13q14
Normal 17p13 Loss 17p13
(focal)
Loss 17p13
(focal)
Table 1 Overview of genetic abnormalites as determined
by FISH, MLPA and microarray-based genomic profiling
(Continued)
17 Normal 11q22 Not done Gain 12 CNLOH 2q
Gain 12 (21%)
Normal 13q14
Normal 17p13
18 Normal 11q22 Not done Loss 13q14 Loss 1q
Normal 12 Loss 4p
Loss 13q14
(75%)
Loss 15q15
(MGA)
Normal 17p13
19 Not done Not done Normal
20 Normal 11q22 Not done ? loss 13q14 CNLOH 6q
Normal 12 CNLOH 20q
Loss 13q14 (5%)*
Normal 17p13
21 Normal 11q22 Not done Loss 13q14 Loss 2p
Normal 12 Loss 8q
Loss 13q14 (60%) Loss 10q24
Normal 17p13 CNLOH 17p
22 Normal 11q22 Not done Normal
Normal 12
Normal 13q14
Normal 17p13
23 Loss 11q22 (77%) Not done Loss 11q22
Normal 12 Loss 13q14
Loss 13q14 (50%)
Normal 17p13
24 Normal 11q22 Not done Gain 12 Gain 2q
Gain 12 (21%)
Normal 13q14
Normal 17p13
25 Loss 11q22 (56%) Not done Loss 11q22 Gain 2p
Normal 12 Loss 4q
Normal 13q14 Loss 5q
Normal 17p13 CNLOH 7pq
Loss 10p
Loss 11q
Loss 18q
Gain 21q
26 Normal 11q22 Not done Gain 12
Gain 12 (38%)
Normal 13q14
Normal 17p13
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Abnormalities identified by microarray-based profiling
but not by FISH or MLPA
Sixteen of the 28 patients (57%) carried additional genetic
abnormalities (among which focal CNAs and CNLOH),
not detected by FISH and/or MLPA. Twenty-four CNAs
larger than 5 Mb, outside the loci tested by FISH and/or
MLPA, were identified in 12 different cases (cases 3, 4, 7,
9, 10, 11, 12, 15, 21, 24, 25 and 28) (Tables 1 and 2). Al-
though the clinical impact of these CNAs still has to be
determined, recurrently affected regions such as gain of
the short arm of chromosome 2 including theMYCN gene
(cases 4, 9 and 25), loss of the long arm of chromosome 6
(cases 9, 12 and 28), and gains of chromosomes 18 and 19
(case 15) were noted. In addition, genomic complexity, de-
fined as 3 or more >5 Mb CNAs, was observed in 11 cases
(cases 3, 4, 7, 9, 10, 11, 12, 15, 21, 25, 28). Focal losses not
observed by FISH and/or MLPA and below the level of
cytogenetic resolution (<5 Mb), but containing cancer
genes listed in (http://cancer.sanger.ac.uk/cancergenome/
projects/census), were identified in 5 cases (cases 9, 16, 18,
21 and 25; Table 2). Case 16 harbors a focal TP53 loss
which was not identified by FISH (see above), but could
be identified by MLPA and both microarray platforms
(Figure 1B). Of interest, one patient (case 18) was found to
harbor a recently identified recurrent loss on chromosome
15q15, which includes theMGA gene (Figure 1C), another
patient (case 21) showed a recurrent loss on chromosome
10q24, which includes the NFKB2 gene [5] and a third
patient (case 25) showed a loss on chromosome 4q31
which encompasses the FBXW7 gene [7]. In addition,
focal CNAs involving the known cancer genes SPECC1,
WHSC1, TPR, FIP1L1, PICALM, ZBTB16, PAFAH1B2,
PCSK7, and CTDP1 (cases 9, 18 and 25) were identified.
Since their involvement in CLL has not been reported
before, their clinical significance is still unclear.
CNLOH was detected in 5 cases (cases 3, 17, 20, 21
and 25) and was often found to coincide with several
recurrently affected regions in CLL, including 13q14
in case 3 and 17p in case 21 (Figure 1E). Of interest,
in this latter case a homozygous pathogenic TP53
mutation was identified by targeted DNA sequencing
(data not shown).
Previously, it has been suggested that the size of the
13q14 deletion may influence the clinical prognosis [8,9],
i.e. patients with deletions encompassing the minimally
deleted region (MDR) and smaller than <2 Mb in size
(Type I deletions) were found to exhibit a better clinical
prognosis as compared to patients with larger deletions
often including the RB1 locus (Type II deletions) [9]. A
concomitant advantage of microarray-based genomic pro-
filing is that the size of the 13q14 deletion can directly be
delineated, whereby cases with Type I and Type II dele-
tions can be discerned. In our panel, 7 cases (cases 2, 6, 8,
18, 20, 27 and 28) with a Type I and 6 other cases (cases 3,
4, 11, 16, 21 and 23) with a Type II deletion could be iden-
tified in this way (Table 2). In another case (11) we add-
itionally observed alternating regions of gains, losses and a
normal copy number status involving chromosomes 3 and
11 (Figure 1D), both fulfilling the definition of chromo-
thripsis and reflecting genomic instability [10].
Discussion
In the present study we evaluated the efficacy of
microarray-based genomic profiling in comparison to
routinely applied techniques such as FISH and MLPA in
the genetic diagnosis of CLL. One important benefit of
microarray-based genomic profiling is its ability to de-
tect chromosomal aberrations not detected by routinely
used targeted probe-based assays such as FISH and MLPA,
but with clinical relevance. Although in the recent past
CLL has been studied using a wide range of genomic mi-
croarrays [5,6,11-16], these studies were mainly focused on
the putative prognostic significance of newly identified
genomic alterations. The specific aim of our study was to
assess the efficacy of two recently launched high resolution
microarray platforms (i.e., CytoScan HD and HumanOm-
niExpress) in a clinical diagnostic setting, with special em-
phasis on its limit of detection and resolution.
From our results we conclude that both microarray
platforms performed equally well with respect to detect-
ing genomic alterations (both CNAs and CNLOH). This
performance was assessed by applying identical inter-
pretation criteria (see Methods section), thereby empha-
sizing the importance of applying uniform (international)
interpretation criteria, especially when microarray-based
genomic profiling will increasingly be used in clinical diag-
nostic settings.
Since in a routine clinical diagnostic setting parallel
microarray-based assays using matched normal DNAs
will not be feasible, we have established stringent inter-
pretation criteria based on previous microarray studies
Table 1 Overview of genetic abnormalites as determined
by FISH, MLPA and microarray-based genomic profiling
(Continued)
27 Normal 11q22 Not done Loss 13q14*
Normal 12
Loss 13q14
(86%)*
Normal 17p13
28 Normal 11q22 Not done Loss 13q14 Loss 6q
Normal 12 Loss 17p13 Loss 15q
Loss 13q14 (33%) Gain 17q
Loss 17p13 (39%)
*Bi-allelic loss as determined by FISH (loss of both hybridization signals), MLPA
(RCN below 1) or microarray (log2 ratio below 1).
CNLOH: Copy Neutral Loss Of Heterozygosity.
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Table 2 Details of microarray-based genomic profiling
Patient ID CytoScan HD Array HumanOmniExpress Array Genes in CNAs <5 Mb Type of 13q14
deletion
1 (1–22)x2,(XY)x1 Not done
2 13q14.2q14.3(50,584,486-51,470,499)x1 Not done DLEU2 DLEU1 DLEU7 I
3 6p21.1p11.2(41,934,382-57,160,585)x1 Not done
13q14.2q14.3(48,722,871-51,051,951)0 ~ 1 RB1 DLEU2 DLEU1 II
13q14.11qter(43,405,208-115,095,705)x2 hmz (bi-allelic)
17pterp11.2(526–21,90,786)x1
4 2pterp13.3(12,771-69,686,286)x3 Not done
6pterp21.33(159,975-31,799,736)x1
7q36.1qter(149,853,609-159,119,707)x1
11q13.5q23.3(76,888,344-116,354,467)x1
13q14q14.3(40,480,469-52,003,234)x1 II
5 1q43(234,529,702-242,132,559)x1 Not done
(12)x3
6 13q14.2(50,195,826-51,850,196)x1 Not done DLEU2 DLEU1 DLEU7 I
13q14.2q14.3(50,650,988-51,342,279)x0 DLEU2 DLEU1 (bi-allelic)
7 1q42.12q42.2(224,729,057-231,273,551)x1 1q42.12q42.2(224,726,060-231,572,255)x1
(12)x3 (12)x3
17pterp11.2(526–21,076,299)x1 ~ 2 17pterp11.2(8,547-22,208,945)x1
8 13q14.2(50,519,996-51,503,800)x1 not done DLEU2 DLEU1 DLEU7 I
9 2pterp14(12,771-67,026,521)x2 ~ 3 2pterp14(12,771-67,026,521)x2 ~ 3
6q14.1q21(80,048,777-111,874,976)x1 6q14.1q21(80,134,141-111,850,742)x1
17pterp11.2(526–18,922,732)x1 ~ 2 17pterp11.2(15,463-22,208,949)x1
17p11.2(19,143,976-22,261,792)x2 ~ 3 17p11.2(19,075,156-21,591,064)x2 ~ 3 SPECC1
20pterp11.1(61,569-25,598,847)x1 ~ 2 20pterp11(75,254-25,581,424)x1 ~ 2
10 (8)x2 ~ 3 (8)x2 ~ 3
17pterp11.2(526–21,439,423)x1 ~ 2 17pterp11.2(8,547-22,002,556)x1
17p11.2qter(21,442,422-81,041,938)x2 ~ 3 17q11.2qter(25,295,032-81,051,007)x3
11 Xq21.33qter(95,976,563-155,233,846)x2 Xq21.33qter(96,042,106-154,821,956)x2
3p25.3q13.12(11,420,458-106,634,792)cth 3p25.3q13.12(11,420,458-106,613,301)cth
11p15.4q23.3(4,388,905-114,957,588)cth 11p15.4q23.3(4,400,801-114,958,994)cth
12q15qter(68,548,174-133,778,166)x3 12q15qter(68,468,711-133,777,645)x3
13q14.2(47,596,800-50,761,018)x1 ~ 2 13q14.2(47,314,896-51,835,485)x1 ~ 2 RB1 DLEU1 DLEU2 II
12 3q22.1qter(133,392,418-197,851,986)x2 ~ 3 Not done
6q23.2qter(133,742,371-170,919,482)x1 ~ 2
17pterp11.1(526–22,261,792)x1 ~ 2
19pterp13.3(260,912-2,638,256)x2 ~ 3
13 (1–22)x2,(XY)x1 Not done
14 (12)x3 Not done
15 (12)x3 Not done
(18)x3
(19)x2 ~ 3
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Table 2 Details of microarray-based genomic profiling (Continued)
16 13q14.2q14.3(49,267,418-52,710,335)x1 ~ 2 13q14.2q14.3(49,253,519-52,418,598)x1 DLEU2 DLEU1 DLEU7 II
17p13.1(7,285,282-7,613,708)x1 ~ 2 17p13.1(7,208,197-7,584,400)x1 TP53
17 2q31.2qter(178,126,546-242,783,384)x2 hmz 2q31.1qter(178,522,104-242,082,222)x2 hmz
(12)x3 (12)x3
18 1q31.1(186,115,025-186,574,022)x1 1q31.1(186,126,099-186,576,930)x1 TPR I
4p16.3(1,817,831-3,332,468)x1 4p16.3(1,824,020-3,326,393)x1 WHSC1
13q14.2q14.3(49,834,338-51,885,720)x1 13q14.2q14.3(49,826,508-51,837,299)x1 DLEU2 DLEU1 DLEU7
15q15.1(41,726,490-42,269,397)x1 15q15.1(41,726,490-42,269,397)x1 MGA
19 (1–22)x2,(XY)x1 (1–22)x2,(XY)x1
20 13q14.2q14.3(49,743,769-51,421,152)x1 ~ 2 DLEU2 DLEU1 DLEU7 I
6pterp22.3(156,975-24,464,741)x2 hmz 6pterp22.1(170,044-27,221,519)x2 hmz
20q11.23qter(36,212,125-62,915,555)x2 hmz 20q11.22qter(32,006,475-62,155,324)x2 hmz
21 2p22.1p16.3(39,286,190-52,873,900)x1 ~ 2 Not done
8q12.1q13.3(56,845,311-71,349,857)x1 ~ 2
10q24(102,832,471-104,451,853)x1 ~ 2 NFKB2
13q14.2q14.3(48,564,169-51,710,957)x1 RB1 DLEU2 DLEU1 II
17pterp11.1(526–22,261,792)x2 hmz DLEU7
22 Not done (1–22)x2,(XY)x1
23 Not done 11q21.1q23.3(99,007,487-116,429,253)x1
13q13.3q14.11(34,736,943-41,533,052)x1
13q14.2q31.1(46,831,590-81,829,786)x1 II
24 Not done 2q31.1q37.3 (178,522,104-242,082,222)x3
(12)x3
25 Not done 2p25.3p11.2(18,674-88,509,321)x3
4q12(53,897,152-54,418,635)x1 FIP1L1
4q31.3(153,069,783-154,890,126)x1 FBXW7
5q21.2q35.3(104,253,119-180,693,127)x3
7pterq21.2(57,660-92,377,183)x2 hmz
10p15.3p12.3(111,955-20,876,388)x1
11q14.1q14.2(84,356,651-87,287,369)x1 PICALM
11q22.3-q23.1(107,154,315-112,417,074)x1
11q23.2(113,500,513-114,995,252)x1 ZBTB16
11q23.3(116,042,048-117,199,870)x1 PAFAH1B2 PCSK7
18q22.3q23(73,752,499-78,011,963)x1 CTDP1
21q22.11q22.3(32,065,821-48,042,513)x3
26 Not done (12)x3
27 Not done 13q14.2q14.3(50,583,562-51,545,282)x0 DLEU2 DLEU1 DLEU7 I
(bi-allelic)
28 Not done 6q14.3q24.3(87,140,674-148,617,199)x1
13q14.2q14.3(50,570,191-51,516,305)x1 DLEU2 DLEU1 DLEU7 I
15q13.3q26.1(32,955,095-92,747,286)x1
17p13.3p11.2(103,469-18,820,457)x1
17q11.1q25.3(25,311,244-80,895,745)x3
CNAs: Copy number alterations.
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performed on several types of hematological malignan-
cies [17-19]. These interpretation criteria are set in such
a way that non-tumor-related copy number variants and
CNLOH are excluded. Only gross CNAs (>5 Mb) and
CNLOH (>25 Mb) or those extending to the telomeres
were considered as tumor-associated abnormalities.
Focal CNAs were only considered when they encom-
passed (a) known tumor-related gene(s). In addition, we
excluded variants present in a panel of healthy individ-
uals identified by using the same microarray platforms
(~250 for the HumanOmniExpress and ~1,000 for the
CytoScan HD). This approach allows for the filtering of
background noise such as calling errors and genomic
polymorphisms and, at the same time, allows for the
identification of recurrently affected genomic regions, as
well as regions of potential clinical or biological rele-
vance in CLL.
In order to evaluate the detection limit of the micro-
array platforms, 7 cases (7, 9, 10, 11, 17, 20 and 24) were
selected in which the genomic abnormality was present
in 5-28% of the cells as determined by interphase FISH.
By doing so, both microarray platforms exhibited a high
limit of detection, i.e., CNAs present in at least 16% of
the cells could unambiguously be detected and, in
addition, a bi-allelic loss of 13q14 present in only 5% of
the cells could be observed on the CytoScan HD array
platform. Although in the present study low-mosaic CNAs
present in at least 16% of the cells are readily detected,
log
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Figure 1 Examples of microarray-based genomic profiles. Microarray-based genomic profiles obtained using the CytoScan HD and
HumanOmnioExpress platforms, showing log2 ratios, the log2 ratios smoothened over 10 probes (S-log2) and allele peaks (AP) (case 21 only).
A: loss of the 17p region in case 9 (chromosome 17). B: Focal loss of the TP53 gene in case 16 (showing the chromosome 17p13 region). C: Focal
loss of the MGA gene in case 18 (showing chromosome 15q15.1). D: Chromothripsis of chromosome 11 in case 11. E: No abnormalities in the
log2 ratio and smoothened log2 ratio in case 21. Instead of the 3 expected allele peaks (AA, AB and BB), a pattern showing mainly the AA and BB
alleles is observed on the short arm of chromosome 17, indicating the CNLOH.
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others [6,12,15,16,20] have reported CNAs identified by
FISH (ranging from 10% to ~40% of abnormal cells) that
remained undetected using genomic microarrays. This
may, at least in part, be explained by the microarray plat-
forms used, which appeared to exhibit a lower limit of de-
tection, the choice of the software packages used [14], or
even false-positive FISH results [15].
Despite the fact that we performed microarray-based
genomic profiling on whole peripheral blood samples, and
not on (CD19) enriched cells, we have shown the feasibil-
ity of microarray-based profiling to detect genomic abnor-
malities in peripheral blood samples from CLL patients.
This finding is not unexpected, as CLL is characterized by
a clonal expansion of B cells in peripheral blood. Nonethe-
less, in laboratories that use microarray platforms with a
lower limit of detection, an enrichment step for CD19-
positive cells could improve the detection rate. An internal
check for the presence of sufficient numbers of clonal B
cells in the patient samples can be obtained by analysis of
the microarray profiles for the IGH, IGK and IGL genes,
for which copy number alterations reflect physiological
events accompanied by somatic V(−D-)J assemblies of the
IGH, IGK and IGL genes in the clonal B cell populations
[21,22]. We emphasize the importance of detecting small
CLL clones based on their putative clinical impact in
CLL patients. As yet, there is still some controversy re-
garding the relevance of the size of a 17p deletion clone,
in the range 10% to 25%, which could be associated with
risk stratification and inferior outcome [23,24].
In 16 of the 28 CLL patients included, additional gen-
omic alterations were identified by microarray-based pro-
filing. Although the prognostic impact of many of these
alterations awaits to be defined, an a priori clinical rele-
vance may be assigned to at least some of them. It has
previously been shown that the presence of a high number
of CNAs (ranging from 1 to ≥3 abnormalities >5 Mb),
referred to as genomic complexity, serves as an independ-
ent risk factor for disease progression [11,15,25]. In the
present study genomic complexity (as defined by 3 or
more aberrations ≥ 5 Mb) was detected in 11 cases, and
was found to be associated with other high-risk features,
such as 11q22 loss, 17p13 loss and TP53 mutation in 9 of
these 11 patients.
Eleven of the focal CNAs (smaller than 5 Mb and con-
taining a tumor-related gene) were found to be recurrent,
such as lesions involving the RB1, LEU2, DLEU1, DLEU7,
and TP53 genes, whereas other CNAs encompassed genes
(i.e., MGA, NFKB2 and FBXW7) known to play a role in
CLL [5,7]. In one case (16) we identified a small focal
TP53 loss, which was not detected by FISH. This focal
TP53 loss was detected by both microarray platforms
(Figure 1B) and by MLPA. These latter findings indicate
that microarray-based profiling not only allows the
genome-wide detection of genomic abnormalities, but also
has a higher resolution for detecting clinical relevant focal
lesions as compared to FISH and thus, is of added value.
For the 8 non-recurrent CNAs detected involving tumor-
related gene(s) (cases 9, 18 and 25), their role in the patho-
genesis in CLL is as yet unknown.
Tumor-specific CNLOH was found in 5 cases, and in
2 of these cases the CNLOH involved regions affected
by recurrent CNAs such as 13q14 and 17p13. In the pa-
tient with 17p CNLOH, this genomic aberration was asso-
ciated with a homozygous TP53 mutation. Our CNLOH
observations are consistent with previously published data
in which focal bi-allelic deletions in 13q14 and homozy-
gous TP53 mutations were found within larger CNLOH
regions [5,25,26].
High resolution microarray-based genomic profiling
allows the definition of the size of recurrently deleted re-
gions in CLL. In this way we were able to discriminate
between cases with a large 13q deletion involving the
RB1 gene (Type II deletion) (cases 3, 4, 11, 16, 21 and
23) associated with shorter time to treatment and overall
survival, from those with smaller losses encompassing
the DLEU2, DLEU1 and DLEU7 genes and some micro-
RNAs (MIR15A and MIR16-1) (Type I deletion) (cases 2,
6, 8, 18, 20, 27 and 28) [8,9]. Microarray-based genomic
profiling also allowed the detection of chromothripsis
(case 11). This phenomenon was initially described in
CLL as a new oncogenic event [10]. In an univariate
analysis it has been shown that CLL patients with chro-
mothripsis have an inferior outcome [5].
Conclusion
We here show that both microarray platforms tested ex-
hibit a high limit of detection and resolution to identify
clinically relevant genomic aberrations, including those
that escape routine FISH and/or MLPA-based analyses,
in CLL. In our hands, CNAs present in only 16% of the
cells as determined by FISH can unambiguously be iden-
tified. By applying similar interpretation criteria, results
obtained from different microarray platforms are com-
parable. This opens up the possibility to fully replace the
use of the current FISH panel by microarray-based profil-
ing in all CLL patients. In addition, we show that
microarray-based genomic profiling allows the detection of
putative prognostic relevant abnormalities (i.e., focal TP53
deletions, CNLOH of 17p, size of 13q14 deletions and gen-
omic complexity), that would have remained undetected
by routine FISH and/or MLPA procedures. The ultimate
prognostic value of these novel genomic alterations re-
quires further evaluation in prospective clinical trials.
Methods
Patient samples and DNA isolation
Blood or bone marrow samples were collected from 28
CLL patients from two different institutes (Radboud
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university medical center and University Medical Center
Groningen). The diagnosis CLL was based on standard
morphologic and immunophenotypic criteria [27]. To
determine the limit of detection of both microarray plat-
forms, 7 patients with low percentages of abnormal cells
as determined by FISH were selected from this cohort.
One aliquot of each blood or bone marrow sample was
cultured for 24 hours and a standard cytogenetic cell
preparation was prepared for FISH analysis. From a sec-
ond aliquot DNA was extracted using a QIAamp DNA
mini kit (Qiagen, Venlo, The Netherlands) or the Max-
well Instrument (Promega, Leiden, The Netherlands),
both according to the instructions of the manufacturers.
FISH analysis
The following commercially available probes were used
for FISH: ATM (11q22), centromere 12, D13S319 (13q14)
and TP53 (17p13) (all from Abbott Molecular, Des Plaines,
Illinois). FISH was performed according to the manufac-
turer’s specifications. At least 100 interphase nuclei were
scored by two independent investigators. Overall, there
was a perfect concordance in scoring between the two
investigators. The cut-off values for both gains and
losses were determined by statistical evaluation of FISH
results from control tissues: for each probe the mean +
3 standard deviations of false positive nuclei was taken
as the cut-off level.
MLPA analysis
MLPA was carried out as described before [4] using two
probe sets specifically designed for the detection of genetic
aberrations in CLL, i.e., P037 and P038 (MRC-Holland,
Amsterdam, The Netherlands). Amplified products were
analyzed by capillary electrophoresis on an ABI 3730
genetic analyzer (Life Technologies, Carlsbad, USA). Data
were normalized by dividing each probe’s peak area by the
average peak area of the sample. This normalized peak
pattern was divided by the average normalized peak pat-
tern of all healthy control samples included in the same
experiment. In a diploid situation, i.e., when two DNA
copies are present in all cells, a relative copy number
(RCN) of 1.0 is expected. When a deletion or duplication
is present, the RCN will deviate towards 0.5 or 1.5,
respectively.
Genomic profiling and data analysis
Microarray-based genomic profiling was carried out in a
blinded fashion using two different platforms; the CytoSan
HD array platform (Affymetrix, Inc., Santa Clara, CA,
USA) and the HumanOmniExpress12v1.0 array platform
(Illumina Inc., San Diego, CA, USA). Hybridizations were
performed according to the manufacturer’s protocols.
The data obtained by the CytoScan HD array platform
were analyzed using the Chromosome Analysis Suite
software package (Affymetrix), and for the HumanOm-
niExpress12v1.0 platform data were analyzed using Nexus
copy number software (Biodiscovery Inc., Hawthorne, CA,
USA) using annotations of genome version GRCh37
(hg19).
Interpretation of microarray data in CLL
For a comprehensive analysis of the microarray-based
genomic profiling data we used a previously developed fil-
tering pipeline, and its interpretation was performed using
criteria adapted from [28]: (i) All segments larger than
5 Mb (resolution of conventional karyotyping), regardless
of gene content, were denoted as true aberrations. (ii) All
segments smaller than 5 Mb that coincided with known
cancer genes (http://cancer.sanger.ac.uk/cancergenome/
projects/census/ date of accession November 2012) were
included. (iii) Since paired control DNA was not used, al-
terations that coincided with normal genomic variants
were excluded. For this approach the publicly available
database ‘Database of Genomic Variants’ (http://projects.
tcag.ca/variation/ NetAfix version 32; date of accession
February 2012) and, in addition, the in-house databases in
which CNVs are stored from respectively ~1,000 healthy
individuals run on the CytoScan HD platform and ~250
healthy individuals run on the HumanOmniExpress were
used. (iv) Regions of copy-neutral loss of heterozygosity
(CNLOH), also known as acquired uniparental disomy
(UPD) were only considered if they were >25 Mb in size
or if they extended towards the telomeres of the involved
chromosomes, based on [18,19,29]. (v) Focal CNAs in the
immunoglobulin genes were excluded from this study,
since these lesions generally represent the B-cell clone
with a rearranged immunoglobulin gene.
All the data were also visually inspected to define al-
terations present in a lower proportion of cells, and to
eliminate alterations reported in regions with low probe
density. Only aberrations fulfilling the above criteria were
included in the genomic profiles, and were described
according the standardized ISCN 2013 nomenclature
system [30].
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